Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 14/20 | 1.00 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.57 |
| ▸ | FPR1 | P21462 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | CNR1 | P21554 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14889982 | 1.00 | FPR2 (1.00) | FPR2RAB9AFOLH1FPR1NPSR1 | |
| SCHEMBL16738251 | 0.90 | FPR2 (0.81) | FPR2RAB9AFOLH1FPR1 | |
| SCHEMBL28348394 | 0.90 | FPR2 (0.81) | FPR2RAB9AFOLH1FPR1 | |
| SCHEMBL14889654 | 0.89 | FPR2 (0.79) | FPR2MAPT | |
| SCHEMBL22150311 | 0.89 | FPR2 (0.79) | FPR2MAPT | |
| SCHEMBL14937848 | 0.87 | FPR2 (0.77) | FPR2RAB9ACNR1MEN1LMNA | |
| SCHEMBL16008281 | 0.87 | FPR2 (0.77) | FPR2RAB9ACNR1MEN1LMNA | |
| SCHEMBL15312448 | 0.87 | FPR2 (0.77) | FPR2RAB9ACNR1MEN1LMNA | |
| SCHEMBL14902577 | 0.87 | FPR2 (0.77) | FPR2RAB9A | |
| SCHEMBL18438962 | 0.87 | FPR2 (0.76) | FPR2RAB9AFOLH1FPR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104169254-A | Aryl urea derivatives as n-formyl peptide receptor like-1 (fprl-1) receptor modulators | ALLERGAN INC | 2014-11-26 | — | — | CN | claimed |
| EP-3795148-B1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING OCULAR INFLAMMATORY DISEASES | ALLERGAN INC (US) | 2025-06-18 | — | — | EP | disclosed |
| EP-3795148-A1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING OCULAR INFLAMMATORY DISEASES | ALLERGAN, INC. (US) | 2021-03-24 | — | — | EP | disclosed |
| EP-3795148-A1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING OCULAR INFLAMMATORY DISEASES | ALLERGAN, INC. (US) | 2021-03-24 | — | — | EP | disclosed |
| EP-3078656-B1 | AMIDE DERIVATIVES OF N-UREA SUBSTITUTED AMINO ACIDS AS FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS | ALLERGAN INC (US) | 2020-07-01 | — | — | EP | disclosed |
| EP-2838887-B1 | (2-UREIDOACETAMIDO)ALKYL DERIVATIVES AS FORMYL PEPTIDE RECEPTOR 2 MODULATORS | ALLERGAN INC (US) | 2018-11-21 | — | — | EP | disclosed |
| EP-3088385-A1 | ARYL UREA DERIVATIVES AS N-FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2016-11-02 | — | — | EP | disclosed |
| EP-2776389-B1 | ARYL UREA DERIVATIVES AS N-FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS | ALLERGAN INC (US) | 2016-09-21 | — | — | EP | disclosed |
| CN-104169254-A | Aryl urea derivatives as n-formyl peptide receptor like-1 (fprl-1) receptor modulators | ALLERGAN INC | 2014-11-26 | — | — | CN | disclosed |
| US-8816076-B2 | Aryl urea derivatives as N-formyl peptide receptor like-1 (FPRL-1) receptor modulators | ALLERGAN, INC. (US) | 2014-08-26 | — | — | US | disclosed |
| US-8541577-B2 | Aryl urea derivatives as N-formyl peptide receptors like-1 (FPRL-1) receptor modulators | ALLERGAN, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| WO-2013070600-A1 | ARYL UREA DERIVATIVES AS N-FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2013-05-16 | — | — | WO | disclosed |
| US-20130123496-A1 | ARYL UREA DERIVATIVES AS N-FORMYL PEPTIDE RECEPTORS LIKE-1 (FPRL-1) RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123496-A1 | ARYL UREA DERIVATIVES AS N-FORMYL PEPTIDE RECEPTORS LIKE-1 (FPRL-1) RECEPTOR MODULATORS | FPR1, FPR3, FPR2 | FPR2 3/4885RAB9A 4029/4885FOLH1 1599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.